As VEGF is a key mediator and upregulated in many ocular angiogenic diseases such as proliferative diabetic retinopathy and wet-type age-related macular degeneration, anti-VEGF therapy is the current main strategy of treatment. The gene discussed is VEGFA; the disease is proliferative diabetic retinopathy.